Aytu BioPharma, Inc. (NASDAQ:AYTU) CEO Buys $19,500.00 in Stock

Aytu BioPharma, Inc. (NASDAQ:AYTU) CEO Joshua R. Disbrow purchased 15,000 shares of the stock in a transaction dated Friday, February 28th. The stock was purchased at an average price of $1.30 per share, for a total transaction of $19,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 86,591 shares in the company, valued at approximately $112,568.30. This represents a 20.95 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website.

Aytu BioPharma Price Performance

NASDAQ:AYTU opened at $1.26 on Thursday. Aytu BioPharma, Inc. has a fifty-two week low of $1.23 and a fifty-two week high of $3.45. The stock has a market capitalization of $7.77 million, a P/E ratio of -0.87 and a beta of -1.45. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.81 and a current ratio of 0.98. The company’s 50-day simple moving average is $1.56 and its 200-day simple moving average is $1.88.

Aytu BioPharma (NASDAQ:AYTU) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.28) earnings per share for the quarter. Aytu BioPharma had a negative net margin of 7.62% and a negative return on equity of 19.30%.

Institutional Trading of Aytu BioPharma

An institutional investor recently raised its position in Aytu BioPharma stock. Stonepine Capital Management LLC lifted its stake in Aytu BioPharma, Inc. (NASDAQ:AYTU) by 6.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 500,958 shares of the company’s stock after purchasing an additional 28,489 shares during the quarter. Aytu BioPharma comprises about 0.7% of Stonepine Capital Management LLC’s portfolio, making the stock its 25th largest holding. Stonepine Capital Management LLC owned about 8.15% of Aytu BioPharma worth $1,177,000 as of its most recent filing with the Securities & Exchange Commission. 33.49% of the stock is currently owned by institutional investors and hedge funds.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.